Skip to main content

Table 2 Abstinence rates and odds ratios by treatment condition

From: Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial

  NRT NRT+ VR
Primary outcome: continuous abstinence at week 5–52
 Abstinence, n (%) 23 (10) 29 (12.4) 36 (15.3)
 OR (97.5 % CI) REF 1.28 (0.67–2.43) 1.62 (0.87–3.01)
 Unadjusted
 Adjusted REF 1.34 (0.67–2.70) 1.84 (0.94–3.58)
Secondary outcome: 7-day point prevalence abstinence at week 52
n (%) 34 (14.8) 43 (18.5) 51 (21.7)
 Unadjusted REF 1.31 (0.76–2.25) 1.60 (0.94–2.70)
 Adjusted REF 1.31 (0.79–2.37) 1.84 (1.04–3.26)*
Secondary outcome: continuous abstinence at week 5–22
n (%) 38 (15.8) 59 (24.5) 65 (27.1)
 Unadjusted REF 1.51 (0.88–2.57) 2.01 (1.20–3.36)**
 Adjusted REF 1.67 (0.95–2.94) 2.18 (1.25–3.80)**
Secondary outcome: 7-day point prevalence at week 22
n (%) 38 (15.8) 59 (24.5) 65 (27.1)
 Unadjusted REF 1.72 (1.04–2.85)* 1.96 (1.20–3.23)**
 Adjusted REF 1.87 (1.09–3.20)* 2.09 (1.22–3.57)**
Secondary outcome: continuous abstinence week 5–10
n (%) 72 (29.4) 94 (38.7) 98 (39.8)
 Unadjusted REF 1.52 (1.00–2.30) 1.58 (1.04–2.39)*
 Adjusted REF 1.62 (1.03–2.56)* 1.66 (1.04–2.63)*
Secondary outcome: 7-day point prevalence at week 10
n (%) 65 (26.5) 88 (36.2) 97 (39.4)
 Unadjusted REF 1.57 (1.03–2.41)* 1.79 (1.17–2.73)**
 Adjusted REF 1.65 (1.04–2.61)* 1.89 (1.19–3.01)**
  1. REF, reference group; OR, odds ration; 97.5 % CI, 97.5 % confidence interval; NRT, standard dose, nicotine replacement therapy; NRT+, flexible, dual-form nicotine replacement therapy; VR, varenicline
  2. Adjusted for marital status, income, nicotine dependence, psychiatric status and motivation to quit. *P < 0.025; **P < 0.01